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Simvastatin reduces the blood concentration of cholesterol by inhibiting hydroxymethylglutaryl-coen-
zyme A reductase, the rate-limiting enzyme in cholesterol synthesis, and thereby reduces the risk of
cardiovascular disease. In addition, simvastatin treatment leads to a reduction in ﬂuxes in mitochondrial
respiratory complexes I and II and might thereby reduce the formation of reactive oxygen species, which
have been implicated in the pathogenesis of arteriosclerosis. Therefore, we hypothesized that simvastatin
may reduce oxidative stress in humans in vivo.
We conducted a randomized, double-blinded, placebo-controlled study in which subjects were
treated with either 40 mg of simvastatin or placebo for 14 days. The endpoints were six biomarkers for
oxidative stress, which represent intracellular oxidative stress to nucleic acids, lipid peroxidation and
plasma antioxidants, that were measured in urine and plasma samples.
A total of 40 participants were included, of which 39 completed the trial. The observed differences
between simvastatin and placebo groups in the primary outcomes, DNA and RNA oxidation, were small
and nonsigniﬁcant (p¼0.68), speciﬁcally, 3% in the simvastatin group compared to 7.1% in the placebo
group for DNA oxidation and 7.3% in the simvastatin group compared to 3.4% in the placebo group. The
differences in biomarkers related to plasma were not statistically signiﬁcant between the treatments
groups, with the exception of total vitamin E levels, which, as expected, were reduced in parallel with the
reduction in plasma cholesterol.
In healthy young male volunteers, short-term simvastatin treatment, which considerably reduces
cholesterol, does not lead to a clinically relevant reduction in a panel of measures of oxidative stress.
Whether simvastatin has effects on oxidative stress in diseased populations, such as diabetes or he-
mochromatosis, where oxidative stress is prominent, is unknown but seems unlikely.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The statin group of drugs is widely used to treat hypercholes-
terolemia and to reduce the risk of cardiovascular events in risk
groups [1]. One common side effect of statins is muscle pain, and
the mechanism by which this pain occurs is not fully understood
but could include oxidative stress. Statins have different effects in
skeletal and cardiac muscle, which may be why muscle problemsB.V. This is an open access article u
Pharmacology (Q7642) Co-
løes Vej 26, Entrance 76, DK-are only observed in skeletal muscle [2] and not in other types of
muscles. The primary site of ROS production is in mitochondria
[3,4]. However, there are many sources of ROS, both intracellular
[5] and environmental [6]. Recently, a reduction in mitochondrial
respiration in skeletal muscle was reported in patients treated
with simvastatin. This reduction was mainly related to reduced
respiration in mitochondrial respiratory complexes I and II medi-
ated via a reduction in the content of the electron carrier Q10 [7].
Furthermore, atorvastatin and simvastatin reduced the oxidative
stress induced by calcium [8].
Oxidative stress to RNA can be measured non-invasively based
on the excretion of the ribonucleoside 8-oxoGuo (8-oxo-7,8-dihy-
droguanosine) in urine, and its clinical relevance has beennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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predictive of death [9]. We have hypothesized that RNA oxidation
is related to the production of hydrogen peroxide by mitochondria,
which could contribute to mitochondrial respiration/dysfunction
and excess ROS production in diabetes [10,11]. A reduction in
oxidative stress by statins would therefore represent a novel andFig. 1. Chromatogram tracings from analysis of a urine sample showing the applied ion
and the qualiﬁer ion. The sample concentrations of 8-oxoGuo and 8-oxodG was 14.0 nM
m/z 298.1864207.99 (8-oxoGuo).m/z 298.1864165 (8-oxoGuo qualiﬁer). m/z 287.1864
qualiﬁer).interesting therapeutic mechanism.
We conducted a randomized, double blinded, controlled trial of
simvastatin versus placebo in healthy male volunteers with DNA
and RNA oxidation as the primary endpoints. The secondary
endpoints were the plasma concentrations of malondialdehyde,
vitamin C, vitamin E, and biopterin, which are markers of-traces for each analyte, the 15N5-labelled internal standard (IS), the quantiﬁer ion,
and 14.2 nM, respectively. The transitions are: m/z 303.1864212.99 (8-oxoGuo IS).
196.939 (8-oxodG IS).m/z 282.1864191.939 (8-oxodG). m/z 282.1864150 (8-oxodG
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UPLC gradient program. Eluent A: 5.0 mM ammonium acetate, pH 5. Eluent B:
acetonitrile.
Time (min.) Flow (lL/min) %A %B
0.0 200 100 0
0.5 200 100 0
12.0 200 95 5
14.6 200 10 90
15.0 300 10 90
16.0 300 10 90
17.0 200 100 0
20.0 200 100 02. Materials and methods
2.1. Study design
The study was designed as a randomized, double-blinded,
placebo-controlled intervention study. A total of 40 healthy male
volunteers were recruited, and after informed consent was ob-
tained from the participants, they were randomized to receive a
40 mg simvastatin tablet (N¼20) or a placebo tablet (N¼20) daily
for 14 days. The inclusion criteria were as follows: healthy, Cau-
casian male between 18 and 50 years of age with a BMI between
18 kg/m2 and 30 kg/m2. The recruitment was conducted using
online advertisement and posters at universities and dormitories.
Potential participants received written information if they met the
inclusion criteria. A ﬂow chart of recruitment and randomization is
given in Fig. 1.
The trial was performed at the Laboratory of Clinical Pharma-
cology Q7642, Rigshospitalet from October 2014 to February 2015.
The production of trial medicines and treatment randomization
were performed by Glostrup Apotek (Glostrup, Denmark) accord-
ing to present GMP and ICH guidelines.
The study was approved by the Danish Health and Medicines
Agency (2,014,031,149), the Regional Ethics Committee (H-4–2014-
19) and the Danish Data Protection: (BBH-2014-026/I-suite 2882);
the study is registered at the European Clinical Trials Database
(2014-000959-92) and at clinicaltrials.gov (NCT02256254).
The study was conducted according to Danish law and current
ICH-GCP guidelines. It was monitored by the GCP unit at the Co-
penhagen University Hospital (2014–647).
2.2. Study outcome
The primary endpoint was the individuals’ change in DNA and
RNA oxidation, as determined by the 24 h urine excretion of
8-oxodG and 8-oxoGuo before and after simvastatin treatment
compared to the changes observed in individuals in the placebo
treatment group.
The secondary endpoints were changes in the blood plasma
concentrations of the biomarkers, malondialdehyde [12] (MDA),
vitamin C [13], vitamin E [14] and biopterin [15] between sim-
vastatin treatment and placebo treatment groups.
Compliance levels of at least 65% trial medicine administration
and 75% urine collection were accepted; levels were corrected
from recorded void losses.
2.3. Statistical considerations
An a priory power calculation assuming a type 1 error risk of
5%, a type 2 error risk of 20% and a relevant difference of 20% was
performed and resulted in 20 participants in each group.
The statistical analysis was carried out with SAS version 9.4
(SAS Institute Inc., Cary, NC, USA), and p-valueso0.05 were con-
sidered statistically signiﬁcant.
Variables were tested for normal distribution (Kolmogorov-
Smirnov). The mean changes in each endpoint between the sim-
vastatin and the placebo groups were analyzed using a two-sided,
unpaired t-test.
2.4. Analytical procedures
2.4.1. Chemicals
For this study, 8-oxo-7,8-dihydroguanosine (8-oxoGuo) was
purchased from BioLog (Bremen, Germany) and 8-oxo-7,8-dihydrodeoxyguanosine (8-oxodG) from Berry & Associates (Dex-
ter, MI). The internal standards, 15N5-8-oxodG and 15N5-8-oxoGuo,
were produced in the lab by electrochemical oxidation [16] of
15N5-dG and 15N5-Guanosine, which were purchased from Cam-
bridge Isotope Laboratories (Tewksbury, MA).
Acetonitrile (isocratic grade) was purchased from Merck KgaA
(Darmstadt, Germany). Methanol (HPLC-grade), lithium acetate
dihydrate, acetic acid, and aqueous ammonia (25%) were all from
Sigma-Aldrich (Steinheim, Germany). LC-MS Ultra Chromasolv
water from Sigma-Aldrich was used for preparation of the Lithium
acetate buffer and mobile phase. QC samples were prepared from a
pool of urine samples and stored at –20 °C.
2.4.2. Sample preparation
Urine samples were stored at 20 °C prior to analysis. The
frozen urine was thawed, mixed, and heated to 37 °C for 5 min to
re-dissolve possible precipitates and trapped analytes [17]. The
heated samples were then centrifuged at 10,000 g for 5 min.
Calibration standards in the range of 1.0–60.0 nM and an internal
standard solution were prepared in 0,1 M Lithium acetate, pH 6.4.
The ﬁnal sample preparation in 96-well plates was carried out in a
fully automated process, using a Biomek 3000 (Beckman Coulter,
CA, USA) that mixed 1) 90 mL of 100 mM lithium acetate buffer, 2)
110 mL of urine/calibration standard/QC sample, and 3) 90 mL of
internal standard solution.
2.4.3. Chromatography
The chromatographic separation was performed on an Acquity
UPLC I-class system (Waters, Milford, MA, USA). The column was
an Acquity UPLC BEH Shield RP18 column (1.7 mm, 2.1100 mm)
protected with a VanGuard precolumn (BEH Shield RP18, 1.7 mm,
2.15 mm), and both were from Waters. The column was oper-
ated at 4 °C to focus the analytes at the front end during the in-
jection of 50 mL of sample volume. The mobile phase and gradient
are shown in Table 1.
2.4.4. Mass spectrometry
The MS detection was performed by a Xevo TQ-S triple quad-
rupole mass spectrometer (Waters) that was working in the ne-
gative ionization electrospray mode. The MS-settings were opti-
mized using the Intellistart function (MassLynx 4.1). A desolvation
gas ﬂow of 1000 L/h was applied and heated to 500 °C to ensure a
stable spray of the UPLC mobile phase containing less than 5%
organic solvent. To reduce contamination of the ion source, a
switching valve diverted the mobile phase ﬂow to waste with the
exception of the fraction at the time for elution of the target peaks
(9–14 min).
Detections were performed in the multi-reaction monitoring
mode (MRM). The MS/MS transitions and collision energies are
reported in Table 2. Quantiﬁcation was based on the signal peak
area from the transitions, 298/208 (8-oxoGuo) and 282/192 (8-
oxodG) relative to the signal peak area of the respective internal
Table 2.
Analytical parameters and mass transitions of the MS/MS detection.
Analyte Rt. (min.) Ionization MRM mass transitions (Collision energy) Fragment ratio Qualiﬁer/quantiﬁer
Quantiﬁer Qualiﬁer Internal standard
8-oxoGuo 9.27 ESI(-) 298-208 (20 V) 298-165 (24 V) 303-213 (20 V) 0.28
8-oxodG 11.87 ESI(-) 282-192 (14 V) 282-149 (32 V) 287-197 (14 V) 0.22
Fig. 2. Participant ﬂow for SIMOX. In total, 45 participants were assessed for
eligibility, and 40 were included. Following treatment, one participant was ex-
cluded, and ﬁnally, 39 participants were analyzed.
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oxodG), were applied as qualiﬁer ions to conﬁrm the presence of
the analyte and the absence of false contributions from the co-
elution of similar components in the urine sample. The chroma-
togram traces are shown in Fig. 2.
The signal ratio of the two fragment-ions (qualiﬁer/quantiﬁer)
was calculated for each sample. According to the tolerance
guidelines [18], results were rejected if the fragment ratio in the
urine samples deviated by more than 725% from the mean ratio
of the actual standards.
2.4.5. Validation procedures
The analytical method was validated in accordance with the
FDA guidelines [19], including selectivity, accuracy, precision, lin-
earity, ion suppression and LLOQ. Validation with respect to the
stability of samples and standards was performed in a previous
study [20].
Validation of method selectivity and accuracy was challenged
by the fact that no human urine without detectable endogenous
levels of the studied adducts could be found, and no accredited
reference material was available. The determination of selectivity
was therefore only possible with respect to the internal standards
but not for the analytes, and the analytical accuracy could be de-
termined only from their recovery in urine samples to which dif-
ferent levels of 8oxoGuo and 8oxodG standard solution had been
added.
2.4.6. Limit of quantiﬁcation
The lower limit of quantiﬁcation (LLOQ) was 1.0 nM for both
8-oxoGuo and 8-oxodG based on the quality requirements of CV
o20%.2.4.7. Linearity, precision, and accuracy
For both analytes, linear relationships were obtained in the
concentration range of 1.0–200 nM using a weighting factor of
1/x2. However, as the urine concentration of 8-oxoGuo and 8-ox-
odG rarely exceeds 60 nM, the applied calibration range was lim-
ited to 1–60 nM.
The within-day and between-day variations were estimated
from three series of ﬁve human urine samples, all prepared in
triplicate and ranging in concentration from 3.5 to 48.5 nM. Var-
iation at repeated analyses of the same sample was, on average,
1.4% for 8oxoGuo and 2.7 for 8oxodG (n¼4).
The average within-day precision was 2.9% for 8-oxoGuo and
3.7% for 8-oxodG, and the between-day precision was 1.5% and
3.4%, respectively. As a measure of accuracy, the average recovery
in the human urine samples to which 8-oxoGuo and 8-oxodG had
been added was 98.7% for 8oxoGuo and 95.7% for 8oxodG.
2.4.8. Ion suppression
Ion suppression due to the matrix effects was estimated from
the ratio of the average peak area of the internal standard in the
urine samples to the aqueous calibration standards because
identical amounts of ISTD has been added to the urine samples
and standards. Considerable ion suppression at 42–45% was ob-
served and was calculated as [1–(ISTD peak areaurine)/(ISTDpeak
areabuffer)]100.
2.4.9. Selectivity
As no blank urine samples were available with respect to the
natural occurring analytes, selectivity or speciﬁcity was evaluated
based on the second fragment ion measured. The selectivity re-
quirements were deﬁned as follows: 1) Peaks from the quantiﬁer
ion, as well as the qualiﬁer ion, should both be present in the
chromatogram, and the retention time of the two peaks should not
differ by more than 0.05 min 2) The peak area ratio of the two
peaks should not deviate from the average ratio in the standards
by more than 725%. These requirements were fulﬁlled in all of
the urine samples involved in the validation.
No interfering peaks at the relevant retention times were ob-
served in the MS/MS transition trace of the two internal standards
in the ﬁve urine samples when measured without the addition of
the internal standard.
2.4.10. Drift
Repeated analyses of ﬁve urine samples proved that batches of
at least 220 samples could be analyzed without drift during the
analysis time (ca. 75 h).3. Results
3.1. Study population and ﬂow
The baseline characteristics of the included participants are
presented in Table 3. The physical and biochemical data were
collected at the screening visit as part of their eligibility criteria.
There were no signiﬁcant differences in any of the characteristics
between the two groups.
Table 3.
Baseline characteristics of the included participants. The physical and biochemical
data were collected at the screening visit. Data for compliance were collected at
their ﬁrst and ﬁnal visits. The data are depicted as the means (standard deviation)
and p values.
Placebo Simvastatin
N 19 20
Physical data Mean (SD) Mean (SD) p
Age (yrs.) 25.5 (5.49) 25.2 (6.30) 0.86
Weight (kg) 80.4 (10.85) 79.8 (11.55) 0.99
Height (m) 1.84 (0.10) 1.83 (0.06) 0.86
Body Mass Index (kg/m2) 23.8 (2.47) 23.7 (2.95) 0.95
Biochemical data Mean (SD) Mean (SD)
Ferritin (μg/L) 154.37 (80.44) 135.95 (93.43) 0.51
Hemoglobin (mmol/L) 9.42 (0.44) 9.17 (0.63) 0.16
Iron (μmol/L) 21.95 (5.20) 23.55 (7.07) 0.43
Creatinine (μmol/L) 91.74 (10.19) 89.75 (11.31) 0.57
Total cholesterol (mmol/L) 4.11 (0.75) 4.10 (0.77) 0.97
HDL cholesterol (mmol/L) 1.40 (0.17) 1.46 (0.29) 0.47
LDL cholesterol (mmol/L) 2.41 (0.69) 2.32 (0.76) 0.70
Triglycerides (mmol/L) 0.83 (0.52) 0.85 (0.50) 0.88
Compliance Mean (SD) Mean (SD)
Trial medicine administration (%) 100 (0) 98.9 (3.49) 0.19
Urine collection 1, before (%) 99.7 (1.26) 99.5 (1.51) 0.66
Urine collection 2, after (%) 99.1 (3.16) 99.2 (3.62) 0.94 Fig. 3. Delta values of urinary excretion/24 h of the primary endpoints. 8-oxodG
(circle) and 8-oxoGuo (square) for the placebo (open) and simvastatin (full) groups
are shown. The data are denoted as the mean7SD for the placebo (N¼19) and
simvastatin (N¼20) groups.
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Data for compliance was collected at the participants’ ﬁrst and
ﬁnal visit. The overall urine collection compliance was 92%, and
the overall trial medicine.
administration compliance was 99%.
3.3. Adverse events
The 39 participants who completed the study reported a total
of 57 events. In total, 15 events were assessed as adverse reactions,
but none were serious. No adverse events caused withdrawal or
code breach. The most common adverse events or reactions were
changes in a safety measurement, symptoms of the ﬂu, gastro-
intestinal problems and headaches.
3.4. Primary endpoints
The data for the primary endpoints of the participants who
completed the study are presented in Table 4 and Fig. 3.
There was no statistically signiﬁcant difference in the mean
change in RNA oxidation (8-oxoGuo/24 h) after simvastatin treat-
ment compared to the difference before and after placebo treat-
ment (p¼0.68). The mean difference in RNA oxidation in the
simvastatin group was þ7.3% (95% CL: 9.3–16.6%), and þ3.4%
(95% CL: 10.8–14.2%) in the placebo group.Table 4.
Urinary excretion/24 h of the primary endpoints, 8-oxodG and 8-oxoGuo, for the
placebo and simvastatin groups. The p values were calculated using an unpaired t-
test.
Before After Delta p
Mean (SD) Mean (SD) Mean (SD)
8-oxodG(nM/
24 h)
Placebo
(N¼19)
24.38 (9.65) 26.11 (10.10) 1.73 (5.90)
Simvastatin
(N¼20)
20.62 (7.08) 21.24 (8.17) 0.62 (3.90) 0.49
8-oxoGuo
(nM/24 h)
Placebo
(N¼19)
31.10 (9.05) 32.16 (9.67) 1.06 (7.51)
Simvastatin
(N¼20)
26.19 (5.68) 28.11 (6.42) 1.92 (5.57) 0.68There was no statistically signiﬁcant difference in the mean
DNA oxidation (8-oxodG/24 h) following simvastatin treatment
compared to placebo treatment (p¼0.49), and the difference in
the simvastatin group was 3% (95% CL: 8.3–11.3%) and 7.1% (95%
CL: 10.9–18.0%) in the placebo group.
3.5. Secondary endpoints
The data for the secondary endpoints of the participants who
completed the study are presented in Table 5 and Fig. 4.
The differences between the two treatment groups for MDA
(Fig. 4A), biopterin (Fig. 4B), and Vitamin C (Fig. 4C) were small
and nonsigniﬁcant, with p¼0.60, p¼0.98 and p¼0.78,
respectively.
There was a statistically signiﬁcant difference between the
treatment groups for total vitamin E (p¼0.0003) (Fig. 4D), which
was expected due to the corresponding reduction in LDL observed
in the simvastatin treated group. There were 3.4% and 26.7% re-
ductions in total cholesterol after placebo and simvastatin treat-
ment, respectively, and the LDL cholesterol level was corre-
spondingly reduced by 4.1% and 46.6%. The total reduction of vi-
tamin E was 1.7% after placebo treatment compared to 14% after
simvastatin treatment.4. Discussion
We found that in healthy male volunteers, simvastatin did not
inﬂuence markers of oxidative stress that relate to intracellular
oxidative stress (DNA and RNA oxidation), lipid peroxidation or
plasma concentrations of antioxidant vitamins. These data show
that simvastatin does not reduce oxidative stress in vivo.
The efﬁcacy of simvastatin in the treatment of hypercholes-
terolemia and its use in patients, such as those with type II dia-
betes, is well documented. Additionally, ex vivo, the inhibition of
mitochondrial respiration was demonstrated [7] after treatment
for one year. However, in vivo treatment with simvastatin does not
lead to a reduction of oxidative stress.
Our study was designed as a short-term study lasting 2 weeks.
In cells, simvastatin exposure leads to immediate dose-related
Table 5.
Plasma concentrations of the secondary endpoints, Malondialdehyde (MDA), Biopterin, Vitamin C and Vitamin E, for the placebo and simvastatin groups. The p values were
calculated using an unpaired t-test.
Before After Delta p
Mean (SD) Mean (SD) Mean (SD)
MDA (nmol/mL) Placebo (N¼19) 0.14 (0.045) 0.15 (0.053) 0.0046 (0.046)
Simvastatin (N¼20) 0.16 (0.042) 0.16 (0.041) 0.0018 (0.027) 0.60
Biopterin (nmol/mL) Placebo (N¼19) 0.34 (0.13) 0.33 (0.091) 0.0083 (0.13)
Simvastatin (N¼20) 0.36 (0.10) 0.35 (0.10) 0.0095 (0.10) 0.98
Vitamin C (μmol/L) Placebo (N¼19) 55.01 (20.34) 50.63 (21.36) 4.39 (16.2)
Simvastatin (N¼20) 53.26 (18.77) 50.11 (19.27) 3.15 (10.3) 0.78
Vitamin E (μmol/L) Placebo (N¼19) 22.29 (6.46) 21.91 (5.99) 0.39 (2.75)
Simvastatin (N¼20) 22.12 (3.97) 18.89 (4.75) 3.23 (2.88) 0.0003
Fig. 4. Delta values of plasma concentrations of the secondary endpoints. A) Malondialdehyde (MDA) (rhomb), B) Biopterin, ratio of BH2/BH4 (upward triangle), C) Vitamin C
(hexagon) and D) Vitamin E (downward triangle) for the placebo (open) and simvastatin (full) groups are shown. The data are denoted as the mean7SD for the placebo
(N¼19) and simvastatin (N¼20) groups.
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with a 25% and 50% reduction in plasma and LDL cholesterol
concentrations, respectively. In the study by Larsen et al. [7],
participants took simvastatin for one year. However, that study
showed that simvastatin had a rather small effect on mitochon-
drial respiration, reducing it from 64 to 54 pmol/mg/s, which may
not be clinically relevant and impossible to ﬁnd in vivo, where a
larger number of factors inﬂuence mitochondrial respiration. Lar-
sen et al. also found a reduced concentration of Q10, just as we
found a reduction in vitamin E, which corresponded to the re-
duction in cholesterol. In long-term treatment with simvastatin,
the changes induced in lipid metabolism and lipid soluble anti-
oxidants may take time to manifest. Additionally, these changes
might not be speciﬁc for simvastatin and may be indirect effects
rather than a direct effect of simvastatin on mitochondria.
The previously observed difference between smokers and non-
smokers in DNA oxidation was approximately 50% [20]. In patients
with hemochromatosis [21], RNA oxidation is increased 2–3-fold.
Furthermore, in patients with type 2 diabetes, the highest quartile
versus the lowest quartile differ approximately 2-fold in RNA
oxidation levels [9], and high values of RNA oxidation are asso-
ciated with a considerable risk of premature death in the high
quartile [9]. In the present study, the small, nonsigniﬁcant 7%
difference with an upper 19% conﬁdence limit ensures that the
possibility of overlooking a true difference due to type 2 error is
low and without clinical relevance.
For patients with coronary heart disease, statin therapy re-
sulted in a decrease in MDA [22] as measured by the thiobarbituric
acid reaction (TBA). However, this method is much less speciﬁc for
oxidative stress in vivo than the MDA measurement we used. Inpatients with hypercholesterolemia [23], changes in total anti-
oxidant capacity were found. However, we regard this assay as
being easy to perform but unspeciﬁc and difﬁcult to interpret as
oxidative stress. In vivo studies on hypertensive hypercholester-
olemia mice and humans [24] have also used the unspeciﬁc TBA
reaction for testing the effects of ﬂuvastatin treatment. Similarly,
the TBA reaction has also been used to study effects of ﬂuvastatin,
alone and in combination with the antihypertensive agent, Lo-
sartan, in humans and rats [25]. In summary, as these studies have
used unspeciﬁc methodology [26], their results are very difﬁcult to
interpret. Our study is the ﬁrst to study the anti-oxidative effects
of simvastatin in healthy young males using speciﬁc and validated
methodologies, and based on our ﬁndings, we can reject the hy-
pothesis that simvastatin has antioxidant effects. It is possible that
simvastatin or other statins could have different effects in various
patient populations, such as those mentioned above. Although it is
unknown, there are no indications that the effect on the markers
we have measured for oxidative stress should differ between such
diseased populations and the normal controls investigated in the
present study.
Estimating DNA and RNA oxidation from urine as a biomarker
has limitations, particularly as it reﬂects an average of the in-
tracellular oxidative stress in all cells in the body. Consequently, if
simvastatin has differential effects in other organs, for example,
such as opposite effects in heart and skeletal muscle (5), poten-
tially positive and negative effects could cancel each other out,
thereby obscuring the detection of positive effects in major organs.
Likewise, if the positive effect is conﬁned to a minor organ, such as
the endothelium cells, such an effect, positive or negative, could be
undetectable due to the large background noise from the
S.T. Rasmussen et al. / Redox Biology 9 (2016) 32–3838remainder of the body.
In conclusion, this study demonstrated that in healthy young
male volunteers, simvastatin treatment per se does not reduce
speciﬁc biomarkers for intracellular and extracellular oxidative
stress.Acknowledgement
Supported by a Grant from Region Hovedstaden, Denmark and
the Toyota foundation, Denmark.References
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